Impact of BMI on Long-Term Outcomes in Patients with ST-Segment Elevation Myocardial Infarction after Primary Percutaneous Coronary Intervention

Table 4

Multivariate analysis for major adverse cardiac events according to age.

	≤65 years
	Model 1; ^†OR (95% CI)	value	Model 2; ^‡OR (95% CI)	value
BMI
<24	1		1
24–28	0.436 (0.175–0.927)	0.001	0.741 (0.413–0.979)	0.038
>28	0.360 (0.203–0.636)	<0.001	0.508 (0.344–0.750)	0.016
Diabetes history	5.013 (2.730–8.130)	<0.001	4.286 (2.398–7.660)	<0.001
Lifestyle and medication after discharge
Regular exercise	0.562 (0.382–0.827)	0.003	0.519 (0.351–0.768)	0.002
Beta-blockers	0.524 (0.357–0.770)	0.001	0.508 (0.344–0.750)	0.001
	>65 years
	Model 1; ^†OR (95% CI)	value	Model 2; ^‡OR (95% CI)	value
Diabetes history	2.701 (1.137–6.452)	0.026	2.630 (1.110–6.234)	0.028
Hypertension	3.735 (1.156–9.858)	0.001	3.444 (1.429–8.300)	0.006
Triple disease	2.701 (1.217–5.694)	0.001	2.712 (1.290–5.688)	0.008
Lifestyle and medication after discharge
Regular exercise	0.419 (0.212–0.826)	<0.001	0.472 (0.234–0.951)	0.036
ACEI/ARB	0.394 (0.203–0.763)	<0.001	0.298 (0.144–0.618)	0.001
Bleedings	12.980 (3.879–43.027)	<0.001	12.670 (3.822–42.001)	<0.001

BMI, body mass index; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers. ^†Nonadjusted model. ^‡The multivariable models were adjusted for the following covariate set: age, sex, SBP, DBP, HR, glucose, LDL-C, hypertension, diabetes, stroke, smoking, baseline TIMI flow grade, medication adherence, and bleeding.